Nov 02, 2016 Press Release for Alnylam
Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity
Nov 02, 2016
- Advanced RNAi Therapeutics Pipeline with Eight Active Clinical Programs and Multiple Clinical Data Presentations -
-
- Company Announces Initiation of Expanded Access Program with Patisiran for Patients with Hereditary ATTR Amyloidosis with Polyneuropathy -
- Maintained Strong Balance Sheet with $1.19 Billion in Cash and Remains On Track to End 2016 with Greater than $1.0 Billion in Cash -
"We continue to advance a broad pipeline of investigational RNAi
therapeutics - including 8 programs in clinical development - across a
wide range of disease indications with high unmet need. Despite a
disappointing outcome in our revusiran program, we remain committed to
serving the needs of the ATTR amyloidosis community with patisiran and
to developing RNAi therapeutics with our ESC-GalNAc conjugate platform
as a new class of innovative medicines. Based on a recent recommendation
from the APOLLO Data Monitoring Committee for patisiran and a
comprehensive review of data from over 800 human subjects treated with
RNAi therapeutics - excluding revusiran - for up to nearly three years,
we are encouraged by the overall safety profile for our platform," said
Third Quarter 2016 and Recent Significant Corporate Highlights
-
Advanced patisiran for the treatment of hereditary ATTR amyloidosis
with polyneuropathy (hATTR-PN), also known as familial amyloidotic
polyneuropathy (FAP).
- The Company announced today that it has initiated its patisiran Expanded Access Program (EAP) for patients with hATTR-PN. The patisiran EAP provides an opportunity for eligible hATTR-PN patients, who are unable to participate in an ongoing clinical trial or whose treatment options are otherwise limited, to receive patisiran therapy until the drug becomes commercially available, should it receive approval.
- Announced that the patisiran APOLLO Data Monitoring Committee (DMC) met at the Company's request following its decision to discontinue development of revusiran, and recommended continuation of the APOLLO Phase 3 trial without modification.
- Reported positive initial 24-month data from ongoing Phase 2 open-label extension (OLE) study with patisiran for the treatment of hATTR-PN. Results showed that patisiran can potentially halt or improve neuropathy progression. Patisiran administration was also found to be generally well tolerated in hATTR-PN patients out to 25 months, with no drug-related serious adverse events (SAEs) reported through the data transfer date.
-
Announced decision to discontinue development of revusiran, an
investigational RNAi therapeutic that was being developed for the
treatment of hereditary ATTR amyloidosis with cardiomyopathy
(hATTR-CM).
- The decision was made following the recommendation by the DMC for the ENDEAVOUR Phase 3 trial of revusiran to suspend dosing and the observation of an imbalance in mortality in revusiran-treated patients as compared to those on placebo.
- The Company has initiated a comprehensive evaluation of revusiran data.
- The decision to discontinue development of revusiran does not affect patisiran or any other Alnylam investigational RNAi therapeutic program in development.
-
Advanced fitusiran for the treatment of hemophilia and rare bleeding
disorders (RBD).
- Reported positive interim clinical results from Phase 1 study of fitusiran. Fitusiran achieved a median estimated annualized bleeding rate (ABR) of zero in hemophilia patients without inhibitors. In the initial low-dose cohort of patients with inhibitors, fitusiran achieved antithrombin lowering, increased thrombin generation, and preliminary evidence for reduced bleeding. Fitusiran administration was generally well tolerated in patients with and without inhibitors through the data transfer date.
- Continued dosing hemophilia patients in the ongoing Phase 1/2 OLE study, with up to 16 months of dosing.
- In July, the Company also updated its guidance for Phase 3 initiation, and currently remains on track to start studies in early 2017.
-
Reported
positive interim clinical results from Phase 1 study of ALN-AS1
for the treatment of acute hepatic porphyrias.
- In asymptomatic high excreter (ASHE) porphyria subjects, single and multiple doses of ALN-AS1 achieved rapid, dose-dependent, and durable lowering of aminolevulinic acid (ALA) and porphobilinogen (PBG) - the toxic heme synthesis intermediates that mediate porphyria attacks - of up to 95%, with effects sustained for over ten months after a single dose. ALN-AS1 was generally well tolerated following single and multiple doses through the data transfer date.
-
In addition, both the
United States Food and Drug Administration (FDA) and theEuropean Medicines Agency (EMA) granted orphan drug designation to ALN-AS1 for the treatment of acute hepatic porphyrias.
-
Reported
positive initial clinical results from Phase 1/2 study of ALN-GO1
for the treatment of primary hyperoxaluria type 1 (PH1).
- ALN-GO1 achieved human proof of concept with statistically significant increases in glycolate, a biomarker of effective glycolate oxidase knockdown, in healthy adult volunteers. Single doses of ALN-GO1 were found to be generally well tolerated through the data transfer date.
-
In addition, the Company published pre-clinical data with ALN-GO1
in the
Journal of the American Society of Nephrology (Liebow et al., J Am Soc Nephrol, 2016; doi:10.1681/ASN.2016030338).
-
Reported
initial clinical results from Phase 1/2 study of ALN-AAT for the
treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver
disease and provided program update.
- Results showed that ALN-AAT administration provided potent, dose-dependent, and durable knockdown of serum AAT of up to 88.9%.
- Three instances of asymptomatic, transient elevations of liver enzymes were detected in the highest dose groups. As a result, the Company plans to advance a new Development Candidate, ALN-AAT02.
-
Alnylam's partner, The Medicines Company, announced positive top-line
results from the Day 90 interim analysis in the ongoing ORION-1 Phase
2 study of ALN-PCSsc (also known as PCSK9si), an investigational RNAi
therapeutic for the treatment of hypercholesterolemia.
- ALN-PCSsc achieved significant and durable LDL-C reduction up to Day 90 and was generally well tolerated, including no drug-related liver enzyme elevations, neuropathy signals, or renal function changes.
- Initiated Phase 1/2 clinical trial with ALN-HBV for the treatment of Hepatitis B Virus (HBV) infection.
-
Expanded Alnylam's global footprint with the opening of a new
development and commercial hub in Maidenhead, United Kingdom. The
Maidenhead office joins Alnylam's
Zug, Switzerland office - its European headquarters - in allowing the Company to support planned growth inEurope . -
Expanded Management Team with appointments of
Antoine Barouky , General Manager,France ;Emmanuel Dulac , Ph.D., Senior Vice President, Chief Commercial Officer;Arianna Greco , Vice President, Legal -Europe andCanada ;Yvonne Greenstreet , MBChB, Executive Vice President, Chief Operating Officer;Thomas Hoock , Ph.D., Vice President, Program Lead; andSiva Sakhamuri , Ph.D., Vice President, Manufacturing.
Upcoming Events in Late 2016
-
Alnylam's partner The Medicines Company plans to present initial
results from the ORION-1 Phase 2 study of ALN-PCSsc in a Late-Breaking
Clinical Trial Session at the
American Heart Association (AHA) Scientific Sessions 2016, onNovember 15, 2016 . -
Alnylam announces today that it plans to present clinical data from
multiple pipeline programs at the 58th
American Society of Hematology (ASH) Annual Meeting, being heldDecember 3 - 6, 2016 inSan Diego, California , including:-
Additional data from the Phase 1 study of fitusiran in patients
with hemophilia, including initial data from the Phase 1/2 OLE
study, in poster presentations on:
-
Saturday, December 3 , at5:30 pm PT (patients with inhibitors); -
Sunday, December 4 , at6:00 pm PT (patients without inhibitors).
-
-
Initial data from Part C of the Phase 1/2 study of ALN-AS1 in
acute intermittent porphyria patients with recurrent porphyria
attacks in a poster presentation on
Saturday, December 3 , at5:30 pm PT . -
Longer-term follow-up data from the Phase 1/2 study of ALN-CC5, an
investigational RNAi therapeutic for the treatment of
complement-mediated diseases, in patients with paroxysmal
nocturnal hemoglobinuria (PNH) receiving concomitant eculizumab in
a poster presentation on
Monday, December 5 , at6:00 pm PT .
-
Additional data from the Phase 1 study of fitusiran in patients
with hemophilia, including initial data from the Phase 1/2 OLE
study, in poster presentations on:
-
The Company also announces today that it plans to present initial
clinical results from the Phase 1 study of ALN-TTRsc02, an
investigational RNAi therapeutic for the treatment of ATTR
amyloidosis, at the Company's R&D Day, which will be held the morning
of
Friday, December 16, 2016 inNew York City and will be webcast.
Financials
"Alnylam continues to maintain a strong balance sheet, ending the third
quarter of 2016 with approximately
Cash and Investments
At
GAAP Net Loss
The net loss according to accounting
principles generally accepted in the
Revenues
Revenues were
Research and Development Expenses
Research and development
(R&D) expenses were
General and Administrative Expenses
General and
administrative (G&A) expenses were
Conference Call Information
Management will provide an
update on the company, discuss third quarter 2016 results, and discuss
expectations for the future via conference call on Wednesday, November
2, 2016 at 4:30 p.m. ET. To access the call, please dial 877-312-7507
(domestic) or 631-813-4828 (international) five minutes prior to the
start time and refer to conference ID 7349534. A replay of the call will
be available beginning at 7:30 p.m. ET on
In January 2014, Alnylam and Sanofi
Genzyme, the specialty care global business unit of Sanofi, formed an
alliance to accelerate and expand the development and commercialization
of RNAi therapeutics across the world. The alliance is structured as a
multi-product geographic alliance in the field of rare diseases. Alnylam
retains product rights in North America and Western Europe, while Sanofi
Genzyme obtained the right to access certain programs in Alnylam's
current and future Genetic Medicines pipeline in the rest of the world
(ROW) through the end of 2019, together with certain broader
co-development/co-commercialization rights and global rights for certain
products. In the case of patisiran, Alnylam will advance the product
in North America and Western Europe, while Sanofi Genzyme will advance
the product in the ROW. In the case of fitusiran, Sanofi Genzyme has
elected to opt into the program for its ROW rights, while retaining its
further opt-in right to co-develop and co-promote fitusiran with Alnylam
in
About RNAi
RNAi (RNA interference) is a revolution in
biology, representing a breakthrough in understanding how genes are
turned on and off in cells, and a completely new approach to drug
discovery and development. Its discovery has been heralded as "a major
scientific breakthrough that happens once every decade or so," and
represents one of the most promising and rapidly advancing frontiers in
biology and drug discovery today which was awarded the 2006 Nobel Prize
for Physiology or Medicine. RNAi is a natural process of gene silencing
that occurs in organisms ranging from plants to mammals. By harnessing
the natural biological process of RNAi occurring in our cells, the
creation of a major new class of medicines, known as RNAi therapeutics,
is on the horizon. Small interfering RNA (siRNA), the molecules that
mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target
the cause of diseases by potently silencing specific mRNAs, thereby
preventing disease-causing proteins from being made. RNAi therapeutics
have the potential to treat disease and help patients in a fundamentally
new way.
About LNP Technology
Alnylam has licenses to Arbutus LNP
intellectual property for use in RNAi therapeutic products using LNP
technology.
About
Alnylam is a biopharmaceutical
company developing novel therapeutics based on RNA interference, or
RNAi. The company is leading the translation of RNAi as a new class of
innovative medicines. Alnylam's pipeline of investigational RNAi
therapeutics is focused in 3 Strategic Therapeutic Areas (STArs):
Genetic Medicines, with a broad pipeline of RNAi therapeutics for the
treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of
RNAi therapeutics toward genetically validated, liver-expressed disease
targets for unmet needs in cardiovascular and metabolic diseases; and
Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that
address the major global health challenges of hepatic infectious
diseases. In early 2015, Alnylam launched its "Alnylam 2020" guidance
for the advancement and commercialization of RNAi therapeutics as a
whole new class of innovative medicines. Specifically, by the end of
2020, Alnylam expects to achieve a company profile with 3 marketed
products, 10 RNAi therapeutic clinical programs - including 4 in late
stages of development - across its 3 STArs. The company's demonstrated
commitment to RNAi therapeutics has enabled it to form major alliances
with leading companies including Ionis, Novartis, Roche, Takeda,
Alnylam Forward-Looking Statements
Various statements in
this release concerning Alnylam's future expectations, plans and
prospects, including without limitation, Alnylam's views with respect to
the potential for RNAi therapeutics, including patisiran, fitusiran,
ALN-AS1, ALN-GO1, ALN-AAT02, ALN-PCSsc, and ALN-HBV, its expectations
regarding the timing of clinical studies and the presentation of
clinical data, including for its studies for fitusiran, ALN-AS1,
ALN-CC5, and ALN-TTRsc02, as well as The Medicines Company's study of
ALN-PCSsc, its expectations regarding its patisiran Expanded Access
Program (EAP) for patients with hATTR-PN, its initiation of a
comprehensive evaluation of the revusiran data, its expected cash
position as of
The scientific information discussed in this news release relating to
Alnylam's investigational therapeutics is preliminary and investigative.
None of Alnylam's investigational therapeutics have been approved by the
|
|
||||||||||||||||||||||||||
| UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | ||||||||||||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||||||||||||
|
Three Months Ended |
Nine Months Ended |
|||||||||||||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||||||||||||
| Net revenues from collaborators | $ | 13,651 | $ | 6,324 | $ | 29,705 | $ | 33,546 | ||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||
| Research and development | 97,936 | 68,618 | 277,381 | 193,660 | ||||||||||||||||||||||
| General and administrative | 22,391 | 16,036 | 61,478 | 43,382 | ||||||||||||||||||||||
| Total operating expenses | 120,327 | 84,654 | 338,859 | 237,042 | ||||||||||||||||||||||
| Loss from operations | (106,676 | ) | (78,330 | ) | (309,154 | ) | (203,496 | ) | ||||||||||||||||||
| Other income: | ||||||||||||||||||||||||||
| Interest income | 2,204 | 1,610 | 6,109 | 4,243 | ||||||||||||||||||||||
| Other income (expense) | 401 | (72 | ) | 5,871 | (99 | ) | ||||||||||||||||||||
| Total other income | 2,605 | 1,538 | 11,980 | 4,144 | ||||||||||||||||||||||
| Net loss | $ | (104,071 | ) | $ | (76,792 | ) | $ | (297,174 | ) | $ | (199,352 | ) | ||||||||||||||
| Net loss per common share - basic and diluted | $ | (1.21 | ) | $ | (0.91 | ) | $ | (3.48 | ) | $ | (2.38 | ) | ||||||||||||||
| Weighted-average common shares used to compute basic and diluted net loss per common share | 85,716 | 84,633 | 85,513 | 83,696 | ||||||||||||||||||||||
| Comprehensive loss: | ||||||||||||||||||||||||||
| Net loss | $ | (104,071 | ) | $ | (76,792 | ) | $ | (297,174 | ) | $ | (199,352 | ) | ||||||||||||||
| Unrealized gain (loss) on marketable securities, net of tax | 1,224 | (25,981 | ) | (25,331 | ) | (55,982 | ) | |||||||||||||||||||
|
Reclassification adjustment for realized gain on marketable
securities
included in net loss |
(706 | ) | — | (6,816 | ) | — | ||||||||||||||||||||
| Comprehensive loss | $ | (103,553 | ) | $ | (102,773 | ) | $ | (329,321 | ) | $ | (255,334 | ) | ||||||||||||||
|
|
||||||||||
| UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||
| (In thousands, except share amounts) | ||||||||||
|
|
|
|||||||||
| 2016 | 2015 | |||||||||
| Cash, cash equivalents and marketable securities | $ | 1,039,088 | $ | 1,280,951 | ||||||
| Restricted investments | 150,000 | — | ||||||||
| Billed and unbilled collaboration receivables | 15,146 | 8,298 | ||||||||
| Prepaid expenses and other assets | 20,843 | 18,030 | ||||||||
| Property and equipment, net | 74,219 | 27,812 | ||||||||
| Investment in equity securities of Regulus Therapeutics Inc. | 13,614 | 51,419 | ||||||||
| Total assets | $ | 1,312,910 | $ | 1,386,510 | ||||||
| Accounts payable, accrued expenses and other liabilities | $ | 61,339 | $ | 46,886 | ||||||
| Total deferred revenue | 76,981 | 68,317 | ||||||||
| Total deferred rent | 9,622 | 6,593 | ||||||||
| Long term debt | 150,000 | — | ||||||||
|
Total stockholders' equity (85.8 million and 85.1 million common
shares issued and outstanding and at |
1,014,968 | 1,264,714 | ||||||||
| Total liabilities and stockholders' equity | $ | 1,312,910 | $ | 1,386,510 | ||||||
This selected financial information should be read in conjunction with
the consolidated financial statements and notes thereto included in
Alnylam's Annual Report on Form 10-K which includes the audited
financial statements for the year ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20161102006264/en/
Investors and Media
or
Investors
Source:
News Provided by Acquire Media
For Media Inquiries, please contact:
Christine Akinc
Chief Corporate Communications Officer media@alnylam.com 617-682-4340
For Investor Inquiries, please contact:
Josh Brodsky
VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276
MEDIA KIT
Essential assets and documents related to Alnylam